Literature DB >> 12724229

Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response?

Susan H Wei1, Robert Brown, Tim H-M Huang.   

Abstract

Epigenetic regulation of gene expression has been observed in a variety of tumor types. We have used microarray technology to evaluate the predisposition of drug response by aberrant methylation in ovarian cancer. Results indicate that loss of gene activity due to hypermethylation potentially confers a predisposition in certain cancer types and is an early event in disease progression. Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12724229     DOI: 10.1111/j.1749-6632.2003.tb05979.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  12 in total

Review 1.  Epigenomics and ovarian carcinoma.

Authors:  Leonel Maldonado; Mohammad Obaidul Hoque
Journal:  Biomark Med       Date:  2010-08       Impact factor: 2.851

Review 2.  DNA methylation as a universal biomarker.

Authors:  Victor V Levenson
Journal:  Expert Rev Mol Diagn       Date:  2010-05       Impact factor: 5.225

3.  The ghost in our genes: legal and ethical implications of epigenetics.

Authors:  Mark A Rothstein; Yu Cai; Gary E Marchant
Journal:  Health Matrix Clevel       Date:  2009

4.  Cytostatic drug treatment causes seeding of gene promoter methylation.

Authors:  Anders Bredberg; Walter Bodmer
Journal:  Eur J Cancer       Date:  2007-01-22       Impact factor: 9.162

Review 5.  Epigenetics as a mechanism driving polygenic clinical drug resistance.

Authors:  R M Glasspool; J M Teodoridis; R Brown
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640

6.  Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.

Authors:  Ryan C Chai; Jessica L Vieusseux; Benjamin J Lang; Chau H Nguyen; Michelle M Kouspou; Kara L Britt; John T Price
Journal:  Mol Oncol       Date:  2017-04-11       Impact factor: 6.603

7.  Genome-wide DNA methylation profiling of CpG islands in a morpholino anthracycline derivative-resistant leukemia cell line: p38α as a novel candidate for resistance.

Authors:  Takeshi Asano; Hidehiko Narazaki; Atsushi Fujita
Journal:  Pharmacol Res Perspect       Date:  2016-12-29

8.  Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.

Authors:  Meng Li; Curt Balch; John S Montgomery; Mikyoung Jeong; Jae Hoon Chung; Pearlly Yan; Tim H M Huang; Sun Kim; Kenneth P Nephew
Journal:  BMC Med Genomics       Date:  2009-06-08       Impact factor: 3.063

9.  Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands.

Authors:  Wei Dai; Jens M Teodoridis; Janet Graham; Constanze Zeller; Tim H M Huang; Pearlly Yan; J Keith Vass; Robert Brown; Jim Paul
Journal:  BMC Bioinformatics       Date:  2008-08-08       Impact factor: 3.169

10.  MethyQA: a pipeline for bisulfite-treated methylation sequencing quality assessment.

Authors:  Shuying Sun; Aaron Noviski; Xiaoqing Yu
Journal:  BMC Bioinformatics       Date:  2013-08-23       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.